Osborne Partners Capital Management’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Osborne Partners Capital Management’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-16,800	Closed	-$796K	–	159
2019 Q3	$796K	Hold	16,800	–	–	0.16%	93
2019 Q2	$899K	Hold	16,800	–	–	0.17%	90
2019 Q1	$927K	Hold	16,800	–	–	0.18%	85
2018 Q4	$791K	Sell	16,800 -500	-3%	-$25.7K	0.12%	119
2018 Q3	$1.03M	Sell	17,300 -120	-0.7%	-$7K	0.13%	111
2018 Q2	$953K	Sell	17,420 -200	-1%	-$10.2K	0.13%	111
2018 Q1	$867K	Hold	17,620	–	–	0.12%	116
2017 Q4	$831K	Sell	17,620 -50	-0.3%	-$2.34K	0.11%	121
2017 Q3	$882K	Hold	17,670	–	–	0.12%	119
2017 Q2	$807K	Hold	17,670	–	–	0.11%	115
2017 Q1	$747K	Sell	17,670 -300	-2%	-$12.6K	0.11%	120
2016 Q4	$697K	Hold	17,970	–	–	0.1%	124
2016 Q3	$754K	Hold	17,970	–	–	0.11%	119
2016 Q2	$665K	Hold	17,970	–	–	0.1%	123
2016 Q1	$688K	Hold	17,970	–	–	0.1%	120
2015 Q4	$908K	Hold	17,970	–	–	0.13%	115
2015 Q3	$822K	Hold	17,970	–	–	0.12%	118
2015 Q2	$1.05M	Hold	17,970	–	–	0.14%	116
2015 Q1	$991K	Hold	17,970	–	–	0.13%	117
2014 Q4	$902K	Sell	17,970 -700	-4%	-$34.3K	0.11%	123
2014 Q3	$863K	Hold	18,670	–	–	0.11%	118
2014 Q2	$816K	Hold	18,670	–	–	0.11%	118
2014 Q1	$777K	Sell	18,670 -80	-0.4%	-$3.42K	0.1%	125
2013 Q4	$695K	Hold	18,750	–	–	0.09%	126
2013 Q3	$658K	Hold	18,750	–	–	0.09%	126
2013 Q2	$542K	Buy	+18,750	New	+$533K	0.08%	131

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Osborne Partners Capital Management's PBE Position: Q4 2019 in Review

Osborne Partners Capital Management sold out of Invesco Biotechnology & Genome ETF (PBE) in Q4 2019, closing a stake of 16,800 shares — an estimated $796K sold.

Osborne Partners Capital Management first reported a position in PBE in Q2 2013 and held it in 26 quarters. The position peaked at $1.05M in Q2 2015. 78 funds tracked by Wall St. Rank hold PBE as of Q4 2019.

Osborne Partners Capital Management reported no remaining Invesco Biotechnology & Genome ETF position as of Q4 2019 after selling out during the quarter.
Osborne Partners Capital Management sold 16,800 Invesco Biotechnology & Genome ETF shares in Q4 2019, an estimated $796K.
Osborne Partners Capital Management first reported a position in Invesco Biotechnology & Genome ETF in Q2 2013 and held it in 26 quarters.
Osborne Partners Capital Management's Invesco Biotechnology & Genome ETF position peaked at $1.05M in Q2 2015.
78 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q4 2019.

Based on Osborne Partners Capital Management's 13F filing for Q4 2019, filed 27 Jan 2020.